Please assess the completion status of the following clinical trial:

Trial Title: Bleeding Incidence in VWD Patients Undergoing On-Demand Treatment

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Patients who meet all of the following criteria are eligible for the study:~* Male or female patients aged ≥5.5 years at the time of enrolment~* VWD type 1 (baseline von Willebrand factor activity \[VWF:RCo\], \<30 IU/dL), 2A, 2B, 2M, or 3 according to medical history requiring substitution therapy with a VWF-containing product to control bleeding~* Currently receiving frequent on-demand treatment with a VWF-containing product~* In female patients of child-bearing potential using hormonal contraception, the medication class should remain unchanged for the duration of their study participation~* Voluntarily given, fully informed written and signed consent obtained before collection of any patient data~Exclusion Criteria:~Patients who meet any of the following criteria are not eligible for the study:~* Patients currently on prophylaxis for VWD (except for perioperative prophylaxis) as well as patients having received treatment once a month for menstrual bleeding, but not for any other bleeds~* Patients whose VWD treatment is planned to be switched from on-demand to prophylactic treatment in the next 6 months~* History, or current suspicion, of VWF or FVIII inhibitors~* Medical history of a thromboembolic event within 6 months before enrolment~* Severe liver or kidney diseases as described in the medical records~* Female patients with an existing or suspected pregnancy or who are breast-feeding at the time of enrolment~* Change in hormonal contraception within 6 months before enrolment~* Cervical or uterine conditions causing abnormal uterine bleeding (including infection or dysplasia)~* Other coagulation disorders or bleeding disorders due to anatomical reasons~* Participation in an interventional clinical study during the 6-month of study period~* Inability to complete the patient diary to reliably evaluate the type, frequency, and treatment of BEs during the 6-month study period

- Gender: ALL
- Minimum Age: 66 Months
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients undergoing treatment with a VWF-containing product (Type: None): Patients with type 3, type 2 (except 2N), or severe type 1 VWD undergoing routine on-demand treatment with a VWF-containing product over a period of 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).